Logo image of NKTX

NKARTA INC (NKTX) Stock Fundamental Analysis

NASDAQ:NKTX - Nasdaq - US65487U1088 - Common Stock - Currency: USD

2.34  -0.02 (-0.85%)

After market: 2.34 0 (0%)

Fundamental Rating

3

NKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. NKTX has a great financial health rating, but its profitability evaluates not so good. NKTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NKTX has reported negative net income.
NKTX had a negative operating cash flow in the past year.
NKTX had negative earnings in each of the past 5 years.
In the past 5 years NKTX always reported negative operating cash flow.
NKTX Yearly Net Income VS EBIT VS OCF VS FCFNKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

NKTX's Return On Assets of -20.79% is fine compared to the rest of the industry. NKTX outperforms 77.17% of its industry peers.
NKTX has a Return On Equity of -25.67%. This is amongst the best in the industry. NKTX outperforms 81.59% of its industry peers.
Industry RankSector Rank
ROA -20.79%
ROE -25.67%
ROIC N/A
ROA(3y)-28.84%
ROA(5y)-31.42%
ROE(3y)-35.96%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
NKTX Yearly ROA, ROE, ROICNKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

NKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NKTX Yearly Profit, Operating, Gross MarginsNKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for NKTX has been increased compared to 1 year ago.
The number of shares outstanding for NKTX has been increased compared to 5 years ago.
NKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NKTX Yearly Shares OutstandingNKTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
NKTX Yearly Total Debt VS Total AssetsNKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

NKTX has an Altman-Z score of -0.57. This is a bad value and indicates that NKTX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -0.57, NKTX is doing good in the industry, outperforming 60.71% of the companies in the same industry.
There is no outstanding debt for NKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.57
ROIC/WACCN/A
WACCN/A
NKTX Yearly LT Debt VS Equity VS FCFNKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 12.91 indicates that NKTX has no problem at all paying its short term obligations.
NKTX has a better Current ratio (12.91) than 85.66% of its industry peers.
A Quick Ratio of 12.91 indicates that NKTX has no problem at all paying its short term obligations.
NKTX's Quick ratio of 12.91 is amongst the best of the industry. NKTX outperforms 85.84% of its industry peers.
Industry RankSector Rank
Current Ratio 12.91
Quick Ratio 12.91
NKTX Yearly Current Assets VS Current LiabilitesNKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

NKTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.31%, which is quite impressive.
EPS 1Y (TTM)22.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NKTX will show a small growth in Earnings Per Share. The EPS will grow by 2.70% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.14%
EPS Next 2Y10.2%
EPS Next 3Y1.93%
EPS Next 5Y2.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NKTX Yearly Revenue VS EstimatesNKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NKTX Yearly EPS VS EstimatesNKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTX. In the last year negative earnings were reported.
Also next year NKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTX Price Earnings VS Forward Price EarningsNKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTX Per share dataNKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.2%
EPS Next 3Y1.93%

More info and screens

0

5. Dividend

5.1 Amount

NKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NKARTA INC

NASDAQ:NKTX (1/31/2025, 8:00:01 PM)

After market: 2.34 0 (0%)

2.34

-0.02 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners97.74%
Inst Owner Change0.03%
Ins Owners0.66%
Ins Owner Change8.12%
Market Cap165.13M
Analysts86.67
Price Target15.47 (561.11%)
Short Float %15.21%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.59%
Min EPS beat(2)-4.75%
Max EPS beat(2)25.93%
EPS beat(4)2
Avg EPS beat(4)6.21%
Min EPS beat(4)-4.75%
Max EPS beat(4)25.93%
EPS beat(8)5
Avg EPS beat(8)8.83%
EPS beat(12)7
Avg EPS beat(12)7.8%
EPS beat(16)7
Avg EPS beat(16)3.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.21%
PT rev (3m)-12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.46%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-1.88
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-1.54
FCFYN/A
OCF(TTM)-1.39
OCFYN/A
SpS0
BVpS6.11
TBVpS6.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.79%
ROE -25.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.84%
ROA(5y)-31.42%
ROE(3y)-35.96%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.91
Quick Ratio 12.91
Altman-Z -0.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)849.95%
Cap/Depr(5y)796.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y26.14%
EPS Next 2Y10.2%
EPS Next 3Y1.93%
EPS Next 5Y2.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.3%
EBIT Next 3Y-3.72%
EBIT Next 5Y-9.84%
FCF growth 1Y-34.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.19%
OCF growth 3YN/A
OCF growth 5YN/A